Azenta (AZTA) Stock Forecast & Price Target

Azenta is viewed positively because its core Sample Management Solutions business, which generated $81M of revenue and remains the majority of sales, still has meaningful long-term demand potential as sample management outsourcing expands and automated cold storage adoption deepens, even though F2Q26 showed near-term softness in Auto Stores and Cryo Systems and some large orders slipped. Azenta is also attractive because the company’s balance sheet and free cash flow profile, including $5M of FCF in the period, should help limit downside while management’s guidance reset to $56-59M of FY26 adjusted EBITDA appears to reflect conservatism around a one-time $3M consulting expense rather than a structural deterioration in the business. Azenta is further supported by an expectation that revenue growth can improve toward its long-range plan and that margin improvement can drive strong earnings growth over the next few years, especially if Multiomics stabilizes, capital demand recovers, and accretive M&A or better-than-expected EPS growth supplements operating leverage.

Azenta is facing a deteriorating fundamental profile marked by a revenue and profitability miss, with revenue of $145M down 3% year over year on a constant-currency organic basis, adjusted EBITDA of $8M versus $17M expected, and adjusted EPS of ($0.04) versus $0.12 expected, signaling weaker execution across both Sample Management Solutions and Multiomics. Management’s guidance cuts are especially concerning, as FY26 organic revenue growth was reduced to (2)% to 1% from 3% to 5% and adjusted EBITDA margin guidance was lowered to roughly 10%-11% from about 14%, implying slower demand, less operating leverage, and a more constrained earnings path. The outlook is further weakened by slowing Multiomics demand in North America, which management said remains a weak spot, alongside lowered FY26E and FY27E revenue and EPS estimates and an extended long-range plan from FY28 to FY29, suggesting the company is pushing out its recovery timeline amid macro headwinds and potential margin pressure.